Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2015

View Archived Issues

Tillotts and Numab collaborate on TNF-alpha blockers for inflammatory bowel disease

BEAM alliance formed to combat antibiotic resistance

MRC funds U.K. R&D Vaccines Network

Scripps scientists study mTOR activity in striatum with support from NIH grant

UNCOVER-1 results reveal efficacy of ixekizumab in plaque psoriasis

Cellular Biomedicine to acquire CD40LGVAX vaccine

ASP-8273 well tolerated and active in first-in-human study

Tumor shrinkage observed in the brain with AZD-3759

IPO for Cosmo Pharmaceuticals' Cassiopea subsidiary

Amp biosimilars outlicenses second biosimilar

Blood glucose lowered with AZP-531 in overweight individuals

Avilex Pharma receives Wellcome Trust award to develop ischemic stroke candidate

New molecular imaging probe [99mTc]HYNIC-TCP-1 is selective for colorectal cancer

NanoCarrier files IND application in Japan for phase I trial of NC-6004 in head and neck cancer

Phase II trials of F-351 begin in China

Preclinical data show efficacy of Delenex's DLX-1008 in in vivo models of human glioma

Takeda patents PKR1 antagonists

Chinese team presents antidiabetic compounds

Bayer introduces GLUT-1 inhibitors

Roche discloses autotaxin inhibitors

Cancer Research Technology patents RET inhibitors

TiGenix takes initial steps towards MAA submission for Cx-601

FDA approves Promacta for children age 6 years and older with chronic ITP

No safety concerns during 30 days after first patient dosed with Celyad's NKG2D CAR T-cell therapy

FDA Advisory Committee recommends approval of mepolizumab for severe asthma in adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...